Merck & Co (NY:MRK)

Revolution Medicines Dismisses Merck, Abbvie Buyout Talks While Analyst Say It Is Worth More Than $32B ↗

Today 17:12 EST

When asked about the company’s strategic transactions, CEO Mark Goldsmith said at a conference that the company has a policy of not commenting on rumors or speculation.

The 44th Annual J.P. Morgan Healthcare Conference opened today in San Francisco with an intensity not seen in years, as the healthcare and technology sectors officially merged their futures. The...

The AI-Bio Convergence: Lilly and Nvidia Kick Off JPM26 with Landmark $1 Billion Alliance

Today 11:59 EST

Topics Artificial Intelligence Intellectual Property

Merck In Talks To Acquire Revolution Medicines For About $30B: Report ↗

January 09, 2026

Merck Looks To Buy Cancer Drugmaker Revolution Medicines: Report ↗

January 08, 2026

All three companies are in better shape than most investors are (understandably) presuming.

3 Dividend Stocks to Hold for the Next 10 Years ↗

Today 3:05 EST

The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial...

Topics Bonds

1 Momentum Stock Worth Your Attention and 2 Facing Headwinds

January 11, 2026

Via StockStory

This ETF Is Proof That the Healthcare Rebound Is Real ↗

January 11, 2026

Via MarketBeat

Topics ETFs

Why Revolution Medicines Stock Surged by 11% Today ↗

January 09, 2026

The company might become the latest biotech acquisition story soon.

MoonLake Immunotherapeutics Surges as FDA "De-Risks" Sonelokimab, Reigniting Multi-Billion Dollar Takeover Speculation

Topics Intellectual Property

January 09, 2026

MoonLake Immunotherapeutics (NASDAQ: MLTX) shares have experienced a dramatic resurgence this week, climbing over 40% following a pivotal regulatory update that has effectively cleared the path for its...

Today’s Date: January 9, 2026 Introduction As we enter the first weeks of 2026, Moderna, Inc. (NASDAQ: MRNA) finds itself at a defining crossroads. Once the poster child for the biotech boom of the...

Topics Intellectual Property

Moderna’s Second Act: A 2026 Deep Dive into the Future of mRNA Therapeutics

January 09, 2026

Via PredictStreet

Topics Initial Public Offering Intellectual Property

Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight ↗

January 09, 2026

Pharmaceuticals giant, Merck & Co. Inc. (NYSE: MRK), is reportedly in talks to acquire cancer drug-maker Revolution Medicines Inc. (NASDAQ: RVMD) in a deal potentially valued at between $28 and $32...

Via Benzinga

J&J Cuts Deal With Trump’s White House To Slash Drug Prices And Dodge Tariffs ↗

January 08, 2026

American Trade Resilience: Deficit Hits 17-Year Low as Export Surge and Tariff Shocks Reshape Global Commerce

Topics Government

January 08, 2026

In a landmark shift for the American economy, the U.S. trade deficit has plummeted to its lowest level in 17 years, signaling a profound transformation in global supply chains and domestic production....

The $20 Billion Question: Revolution Medicines Surges as Big Pharma Circles the Pan-RAS Leader

Topics Artificial Intelligence Economy Energy

January 08, 2026

The first week of 2026 has set the biotech sector ablaze, with Revolution Medicines (NASDAQ: RVMD) finding itself at the epicenter of a high-stakes acquisition tug-of-war. Shares of the Redwood...

Neogen Shares Skyrocket as Q2 Earnings Beat Signals Turning Point in 3M Integration Strategy

Topics Intellectual Property

January 08, 2026

LANSING, MI – Shares of Neogen Corporation (NASDAQ: NEOG) experienced a dramatic surge in early trading today, climbing nearly 29% after the food and animal safety leader reported second-quarter fiscal...

As the pharmaceutical industry rings in 2026, the landscape of healthcare investment has shifted from cautious recovery to a full-scale acquisition frenzy. Driven by a looming "super-cliff" of patent...

Topics Earnings Economy

The 2026 Pharma M&A Outlook: Obesity, HIV, and the Biotech Renaissance

January 07, 2026

The Trillion-Dollar Treatment: Eli Lilly Solidifies Dominance as Obesity Drug Boom Enters New Era

Topics Artificial Intelligence Economy Intellectual Property

January 07, 2026

As the calendar turns to early 2026, the global pharmaceutical landscape is being redefined by a single, seismic force: the metabolic health revolution. At the epicenter of this transformation stands...

The big news in the drug sector is the emergence of GLP-1 weight loss drugs, but dig deeper, and you'll find relatively cheap industry giants to consider.

Topics Economy

3 Drug Stocks to Buy at a Discount ↗

January 07, 2026

Date: January 7, 2026 Introduction Moderna, Inc. (NASDAQ: MRNA), once the definitive poster child of the COVID-19 pandemic response, is currently undergoing one of the most significant pivots in the...

Moderna’s Second Act: Analyzing the 2026 Pipeline Pivot and Recent Stock Surge

January 07, 2026

Via PredictStreet

Topics Economy Initial Public Offering Intellectual Property

Merck Initiates Phase 3 KANDLELIT-007 Trial Evaluating Calderasib (MK-1084), an Investigational Oral KRAS G12C Inhibitor, in Combination With KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) in Certain Patients With Advanced NSCLC

January 07, 2026

From Merck & Co., Inc.

Merck to Complete Acquisition of Cidara Therapeutics

January 07, 2026

From Merck Sharp & Dohme

Merck to Hold Fourth-Quarter and Full-Year 2025 Sales and Earnings Conference Call Feb. 3

January 07, 2026

From Merck & Co., Inc.

As the first week of 2026 draws to a close, a distinct shift in market leadership has become the defining story for Wall Street. After a multi-year period where technology and artificial intelligence...

The Great Rebalancing: Why Healthcare is Leading the Market Charge in 2026

January 06, 2026

US Cuts Childhood Vaccine Schedule To 11 Core Shots— What It Means For Vaccine Makers Like Merck And GSK ↗

Topics Artificial Intelligence Economy Government

January 06, 2026

In a move that could impact vaccine-makers like Merck & Co. Inc. (NYSE: MRK), GSK plc (NYSE: GSK), the U.S. government has decided to massively reduce the number of vaccines it recommends for every...

Via Benzinga

Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones? ↗

January 05, 2026

The highest-yielding stocks in the Dow are Verizon, Chevron, and Merck, but should you buy any of them?

Move comes in response to a presidential memorandum issued by President Donald Trump in December, aimed at aligning U.S. vaccination practices with other developed nations.

Topics Stocks

U.S. Scales Back The Number Of Vaccines It Recommends For Every Child ↗

January 05, 2026

Topics Government

Merck to Participate in the 44th Annual J.P. Morgan Healthcare Conference

January 05, 2026

From Merck & Co., Inc.

The 2026 Pharma Reset: How Industry Giants Are Navigating a New Era of Federal Price Controls

January 02, 2026

Yesterday marked the official commencement of the first-ever "Maximum Fair Prices" (MFPs) for ten of the most widely used drugs in the Medicare program, a direct result of the Inflation Reduction Act’s...

BofA Unveils Q1 2026 Top Stock Picks: High-Conviction Bets on AI Infrastructure and Health Care Valuations

Topics Economy Intellectual Property World Trade

January 02, 2026

As the opening bells of 2026 ring across Wall Street, Bank of America Securities has released its highly anticipated "Top 10 U.S. Stock Ideas for Q1 2026." The report, a cornerstone for institutional...